| New oral anticoagulants in elderly patients with atrial fibrillation. | Am J Med | 2013 Apr | 23369212 |
| Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinicalrelevance to pseudoxanthoma elasticum. | Am J Pathol | 2013 Apr | 23415960 |
| Anticoagulant prevention in patients with atrial fibrillation: alternatives tovitamin K antagonists. | Curr Pharm Des | 2013 | 23286429 |
| Review on natural coumarin lead compounds for their pharmacological activity. | Biomed Res Int | 2013 | 23586066 |
| Are medication restrictions before FOBT necessary?: practical advice based on asystematic review of the literature. | Can Fam Physician | 2012 Sep | 22972722 |
| Dabigatran: comparison to warfarin, pathway to approval, and practical guidelinesfor use. | J Cardiovasc Pharmacol Ther | 2012 Sep | 22388002 |
| Management of atrial fibrillation: direct factor IIa and Xa inhibitors or"warfarin shotgun"? | Mt Sinai J Med | 2012 Nov-Dec | 23239209 |
| [Dabigatran as an alternative to warfarin for the prevention of thromboembolismin atrial fibrillation]. | G Ital Cardiol (Rome) | 2012 Nov | 23160016 |
| Underreporting of hemorrhagic and thrombotic complications of pharmaceuticals to the U.S. Food and Drug Administration: empirical findings for warfarin,clopidogrel, ticlopidine, and thalidomide from the Southern Network on AdverseReactions (SONAR). | Semin Thromb Hemost | 2012 Nov | 23086541 |
| Effects of subacute oral warfarin administration on peripheral blood granulocytesin rats. | Food Chem Toxicol | 2012 May | 22342526 |